Dataset Information

Proteome of Schistocephalus solidus (Cestoda) after short- and long-term heating

ABSTRACT: The protein composition of the cestode Schistocephalus solidus was measured in an experiment simulating the transition of the parasite from a cold-blooded to a warm-blooded host. Infective S. solidus plerocercoids obtained from the three-spined stickleback Gasterosteus aculeatus were heated at 40 °C for 1 hour or cultured in vitro at 40 °C and 22 °C for 48 hours. Plerocercoids taken out from the body cavity of sticklebacks immediately after their sacrifice were used as a reference group.

INSTRUMENT(S): Q Exactive HF-X

ORGANISM(S): Schistocephalus Solidus

TISSUE(S): Whole Body

SUBMITTER: Albina Kochneva

LAB HEAD: Ekaterina Vitalevna Borvinskaya

PROVIDER: PXD024166 | Pride | 2022-02-16

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

Items per page:

1 - 5 of 68

Publications

Temperature-induced reorganisation of Schistocephalus solidus (Cestoda) proteome during the transition to the warm-blooded host.

Borvinskaya Ekaterina V EV Kochneva Albina A AA Drozdova Polina B PB Balan Olga V OV Zgoda Victor G VG

Biology open 20211117 11

The protein composition of the cestode Schistocephalus solidus was measured in an experiment simulating the trophic transmission of the parasite from a cold-blooded to a warm-blooded host. The first hour of host colonisation was studied in a model experiment, in which sticklebacks Gasterosteus aculeatus infected with S. solidus were heated at 40°C for 1 h. As a result, a decrease in the content of one tegument protein was detected in the plerocercoids of S. solidus. Sexual maturation of the para ...[more]

PMID: 34787304

Similar Datasets

Project description:In recent years, there has been an increasing tendency to create drugs of various types based on certain commensal bacteria of the human microbiota and their ingredients. This primarily concerns live biotherapeutics (LBPs) and postbiotics. The creation of such drugs, which can be called pharmacobiotics, requires an understanding of the mechanisms of their action and the identification of pharmacologically active ingredients that determine their target properties. As a rule, this is a complex of biologically active substances synthesized by a specific strain, promoted as LBP or postbiotics (including vesicles): proteins, enzymes, low molecular weight metabolites, small RNAs, etc. In this article, we, primarily targeting neuroinflammatory processes, explore the potential of omics technologies, including genomics, proteomics, transcriptomics, and metabolomics, in harnessing the potential of Limosilactobacillus fermentum U-21 for the development of innovative LBP and postbiotic formulations. Metabolomics and proteomics were employed to elucidate the underlying mechanisms governing the unique attributes of L.fermentum U-21, with particular emphasis on the potential for utilizing its vesicles in postbiotic production. This study utilizes cutting-edge proteomic techniques to identify and quantify the proteins expressed, shedding light on their functional attributes and potential applications. Furthermore, metabolomic analysis provides valuable insights into the small-molecule metabolites produced during fermentation, which made it possible to detect compounds with anti-neuroinflammatory activity. As a result, metabolites and proteins potentially responsible for the immunomodulatory, anti-neuroinflammatory and neuromodulatory activities that were detected in the strain in previous experiments, were identified, including in vesicles. We have shown that L.fermentum U-21 is capable of synthesizing: GABA, Niacin, cyclo(Leu-Gly), Aucubin, chaperone proteins with potential disaggregase activity, and the chemical chaperone scyllo-inositol.

			Action	DRS
	12_1_2018_40C_1h.raw	Raw
	12_2_2018_40C_1h.raw	Raw
	12_3_2018_40C_1h.raw	Raw
	13_1_2018_40C_1h.raw	Raw
	13_2_2018_40C_1h.raw	Raw